ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

In Brief: Breast Cancer Projects To Pay For Concurrent Pathology Review; Laetrile Study Entry Closed

May 19, 1978

RAC Grumbles, Gives Healy Guidelines For Compassionate Use Of Gene Therapy

January 22, 1993

Slamon, Sherr Win Landon-AACR Prizes

March 7, 2003

NIH Draft Guidelines On Stem Cell Research Limit Funds To Cells From In Vitro Fertilization

April 24, 2009

Fewer New Grants Funded Under President’s Proposal.

February 11, 2000

Promising Areas Of Research Listed By NCAB Subcommittee

February 12, 1982